InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (40 ops.)
Explore the complete record of transactions filed by HRUSOVSKY E KEVIN, Former Executive Chairman and former Chief Executive Officer. Officer active across 2 companies, notably Quanterix Corp. In total, 42 reports have been recorded. Total volume traded: €3.9m. The latest transaction was filed on 2 June 2022 — Cession. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations42 total
1,379 shares
Common Stock, par value $0.001
SEC:0001562180-22-005197:0·
€11,572712 shares@ €16.25290.0089% mcap0.3% of flow
Common Stock
SEC:0001562180-22-004770:0·
€11,071522 shares@ €21.20820.0085% mcap0.3% of flow
Common Stock
SEC:0001562180-22-003674:0·
025,594 shares0
Common Stock
SEC:0001562180-22-003552:0·
€23,356868 shares@ €26.90750.018% mcap0.6% of flow
Common Stock
SEC:0001562180-22-003219:0·
€11,992431 shares@ €27.82350.0093% mcap0.3% of flow
Common Stock
SEC:0001562180-22-002275:0·
€41,7621,364 shares@ €30.61710.032% mcap2.2% of flow
Common Stock
SEC:0001562180-22-001270·
€41,7621,364 shares@ €30.61710.032% mcap1.1% of flow
Common Stock
SEC:0001562180-22-001270:0·
€11,930431 shares@ €27.68030.0092% mcap0.6% of flow
Common Stock
SEC:0001562180-22-001135·
€11,930431 shares@ €27.68030.0092% mcap0.3% of flow
Common Stock
SEC:0001562180-22-001135:0·
€136,8833,715 shares@ €36.8460.11% mcap7.4% of flow
Common Stock
SEC:0001562180-22-000229·
€136,8833,715 shares@ €36.8460.11% mcap3.5% of flow
Common Stock
SEC:0001562180-22-000229:0·
€127,1863,579 shares@ €35.53690.098% mcap6.9% of flow
Common Stock
SEC:0001562180-21-007443·
€127,1863,579 shares@ €35.53690.098% mcap3.3% of flow
Common Stock
SEC:0001562180-21-007443:0·
€41,954900 shares@ €46.61610.032% mcap2.3% of flow
Common Stock
SEC:0001562180-21-006965·
€41,954900 shares@ €46.61610.032% mcap1.1% of flow
Common Stock
SEC:0001562180-21-006965:0·
€114,1042,526 shares@ €45.17180.088% mcap6.1% of flow
Common Stock
SEC:0001562180-21-006834·
€114,1042,526 shares@ €45.17180.088% mcap2.9% of flow
Common Stock
SEC:0001562180-21-006834:0·
€82,0271,900 shares@ €43.17220.063% mcap4.4% of flow
Common Stock
SEC:0001562180-21-006622·
€82,0271,900 shares@ €43.17220.063% mcap2.1% of flow
Common Stock
SEC:0001562180-21-006622:0·
€16,429400 shares@ €41.07310.013% mcap0.9% of flow
Common Stock
SEC:0001562180-21-006230·
€16,429400 shares@ €41.07310.013% mcap0.4% of flow
Common Stock
SEC:0001562180-21-006230:0·
€133,4853,175 shares@ €42.04240.10% mcap7.2% of flow
Common Stock
SEC:0001562180-21-005792·
€133,4853,175 shares@ €42.04240.10% mcap3.4% of flow
Common Stock
SEC:0001562180-21-005792:0·
€168,2904,200 shares@ €40.06890.13% mcap9.1% of flow
Common Stock
SEC:0001562180-21-005417·
25 of 42 declarations
About HRUSOVSKY E KEVIN
E. Kevin Hrusovsky is a well-known life sciences and precision diagnostics executive with a long association with Quanterix Corp. At Quanterix, a U.S.-listed company, he served as Chairman of the Board beginning in June 2014 and became President and Chief Executive Officer in January 2015. In April 2022, as part of a succession plan, he moved into the role of Executive Chairman, and he later stepped down from that position in August 2022. His tenure is widely associated with Quanterix’s transformation from a small innovative company into a public proteomics leader focused on ultrasensitive biomarker detection.([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-announces-resignation-kevin-hrusovsky-executive?utm_source=openai)) Throughout his time at Quanterix, Hrusovsky was described by the company as a growth-oriented leader with a strong emphasis on innovation, team building, and strategic clarity. Company materials highlight his role in strengthening the leadership team, shaping the company culture, and guiding expansion across both commercial and scientific fronts. Under his leadership, Quanterix emphasized applications in oncology, neurology, cardiology, inflammation, and infectious disease, while advancing technologies intended to support earlier disease detection and improved treatment insights.([biospace.com](https://www.biospace.com/quanterix-announces-kevin-hrusovsky-chairman-and-chief-executive-officer-and-founder-of-powering-precision-health-as-ey-entrepreneur-of-the-year-2019-award-winner-in-new-england?utm_source=openai)) Hrusovsky is also linked to Powering Precision Health, an initiative he founded to advance the broader precision health agenda and encourage collaboration across science, industry, and clinical innovation. His leadership style has been characterized in company communications as transparent, passionate, mission-driven, and team-focused. From a corporate governance perspective, his career reflects an executive who led a public biotechnology company through growth phases, capital markets development, operational scaling, and a managed leadership transition.([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-ceo-and-powering-precision-health-founder-kevin?utm_source=openai))
